A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 18 Oct 2017 to 9 Oct 2017.
    • 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Trial phase has been change from phase 4 to phase 3 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top